Business Wire

OPSMILL

28.5.2024 12:01:28 CEST | Business Wire | Press release

Share
OpsMill Transforms Infrastructure Automation with Beta Release of Open Source Infrahub

OpsMill, a pioneer in infrastructure and network automation, today announced the beta release of its open source Infrahub platform. Infrahub unifies previously disparate automation capabilities into a single platform, enabling IT teams to transform all their data center, cloud, network, and security infrastructure operations with scalable and consumable automation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528726475/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Infrahub brings the worlds of infrastructure-as-code and infrastructure management together in a single platform (Graphic: Business Wire)

“I’ve spent years building automation systems for infrastructure and network management across a variety of organizations. At every stop, I encountered the same challenges: Managing network and cloud infrastructure required the use of a confusing, cumbersome, costly mix of solutions. These tools were always hampered by serious technical limitations, such as inflexible data models,” said Damien Garros, CEO and co-Founder, OpsMill. “With the release of Infrahub’s open beta, we’ve drawn on years of experience to solve those challenges. This is the first platform that unites the GitOps Infrastructure-as-Code approach with an extensible structured data model. By combining these two approaches, Infrahub frees infrastructure and automation teams from having to integrate and maintain a fragile set of tools. Instead, they can focus on driving innovation through better automation.”

Infrastructure automation has suffered from an unhelpful divide between GitOps and traditional infrastructure management approaches that prevents teams from gaining the critical advantages and best practices of both approaches. GitOps, an automation approach used by many software development teams, offers version control and continuous integration (CI) validation, which are critical for maintaining an accurate data model while scaling automation use. However, GitOps doesn’t offer a structured data model that most easily represents IT infrastructure components and their many inter-linkages. Traditional infrastructure management approaches offer infrastructure-friendly structured databases, but don’t include version control or CI, and are constrained by fixed data models that limit their flexibility.

Infrahub unifies the best of both worlds in a single platform, including the following key capabilities:

  • Extensible Graph Database: Infrahub overcomes the limitations of source-of-truth databases that come with fixed schemas. It is built on an extensible, knowledge-graph database that is ideal for representing and querying the many interrelationships between infrastructure components. Infrahub’s flexible data model means that it can scale across data centers, clouds, networks, and security infrastructure and use cases.
  • Version Control: Infrahub makes versioning possible for your entire data model and all the data populated into that model. This means that multiple members of your team can, in parallel, create a branch of the entire infrastructure database, update an infrastructure component in the database in order to generate configuration files for a network change, then merge the updates back into the database. Native versioning of a centralized and extensible infrastructure database is a key innovation of Infrahub.
  • Artifact Rendering: Infrahub doesn’t leave you alone in managing the generation of artifacts such as configuration files or reporting data files. It includes native artifact rendering as a native platform capability.
  • Continuous Integration (CI): Infrahub has built in the process for performing CI validations to ensure quality control over configuration and data changes.

“As someone who has engineered large backbone networks and helped build a company that relied on extensive network and cloud infrastructure, I’ve seen firsthand how much organizations struggle with scalable and maintainable automation,” said Raphael Maunier, COO and co-Founder, OpsMill. “Infrastructure teams often need their own dev teams just to gather data and build infrastructure, leading to high maintenance costs and slowed innovation. OpsMill was founded to change this. Infrahub provides all the key elements for scalable infrastructure and network automation success, allowing teams to focus on innovation instead of maintaining custom software.”

The open beta version of Infrahub is available now. Visit GitHub to get started today.

About OpsMill

OpsMill is the infrastructure automation platform company, bringing the best practices and features of the industry’s leading automation approaches together in a single, scalable, and extensible platform so that infrastructure, cloud, network, and security teams can focus on innovation rather than integrating toolsets. Infrahub by OpsMill is the industry’s leading open-source integrated infrastructure automation platform. OpsMill is backed by Serena Capital, Partech, OVNI Capital, Kima Ventures and Better Angle. For more information, visit OpsMill.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528726475/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye